Merck anesthesia-reversal agent faces new delay
March 15 (Reuters) - The U.S. Food and Drug Administration will not complete its review of Merck & Co's experimental medicine to reverse the effects of anesthesia until the second half of 2013, representing a three month delay, the drugmaker said.
Merck acquired the product, called sugammadex, through its merger in 2009 with Schering-Plough Corp. It has faced numerous previous regulatory delays, but is deemed by many industry analysts and doctors as one of the biggest potential breakthroughs in anesthesia in recent decades.
March 15- The U.S. Food and Drug Administration will not complete its review of Merck& Co's experimental medicine to reverse the effects of anesthesia until the second half of 2013, representing a three month delay, the drugmaker said.